Cure My Disease

Don't miss your cure!

 Log in / Sign up

Biosimilar for breast cancer tracked in real-world study

NCT ID NCT07542496

Recruiting now Knowledge-focused Sponsor: Société Algérienne de Formation et Recherche en Oncologie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This observational study is following 1,000 people with HER2-positive breast cancer who are receiving a pertuzumab biosimilar as part of their routine care. The goal is to see how doctors are using the drug and how well it works in both neoadjuvant (before surgery) and first-line metastatic settings. Researchers will track treatment patterns, response rates, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pertuzumab biosimilar
What this could lead to
If successful, this study could provide real-world evidence on how well a pertuzumab biosimilar works for breast cancer outside of controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be influenced by patient selection and other factors. It does not test a new drug, only tracks existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HER 2 POSITIVE BREAST CANCER

Contacts and locations

Locations

  • CAC BLIDA, Algiers, Algeria 16000

    RECRUITING

    Algiers, Algeria

    Contact Email: •••••@•••••

  • CHU Béni Messous, Algiers, Algeria 16000

    RECRUITING

    Algiers, Algeria

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.